213.84 0.00 (0.00%)
After hours: 4:17PM EDT
|Bid||202.09 x 100|
|Ask||222.00 x 100|
|Day's range||212.04 - 215.90|
|52-week range||207.99 - 218.00|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Thermo Fisher Scientific (TMO) released its 1Q18 earnings results on April 25, 2018. It registered robust sales, exceeding estimates. It posted net income of $579 million, or $1.43 per share, registering YoY (year-over-year) growth of ~5%. Its adjusted EPS (earnings per share) was $2.50, representing YoY growth of ~20% and coming in ahead of analysts’ estimate of $2.40.
On April 25, Thermo Fisher Scientific (TMO) announced its earnings results for 1Q18, which ended on March 31. Its revenues grew ~23% to ~$5.9 billion YoY (year-over-year). The sales results came in ahead of analysts’ estimate of ~$5.6 billion.
Thermo Fisher's (TMO) performance in Q1 benefits from a series of product launches alongside a major progress in precision medicine initiatives.
On a per-share basis, the Waltham, Massachusetts-based company said it had net income of $1.43. Earnings, adjusted for one-time gains and costs, were $2.50 per share. The results beat Wall Street expectations. ...
Let's take a look at the factors that are likely to influence the earnings results of a few MedTech bigwigs within the broader Medical universe.
Jim Cramer shares his take on callers' favorite stocks at lightning speed, including an industrial play.
Thermo Fisher Scientific (TMO) will announce its 1Q18 earnings results for the quarter ended March 31, 2018, on April 25. For some of the recent partnerships and launches, take a look at Thermo Fisher Launches New Products in Semiconductor Manufacturing. Let’s take a look at what Wall Street expects for the company’s 1Q18 earnings results.
Thermo Fisher (TMO) benefits from its acquisition of FEI, consistently adding stimulus to its analytical instruments portfolio for over a year now.
MUNICH , April 10, 2018 /PRNewswire/ -- Analytica 2018 -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today unveiled an expanded portfolio of new instruments and software ...
The Zacks Analyst Blog Highlights: Amgen, FedEx, Thermo Fisher, Sherwin-Williams and Ameriprise
As of March 15, 2018, Thermo Fisher Scientific (TMO) was trading at a forward PE (price-to-earnings) ratio of 19.2x. The stock has a current PE ratio of 34.9x. For the calculation of the forward PE multiple of a company, the company’s current stock price is divided by the next 12-month earnings estimates for the company. The multiple is an estimate of the potential growth of the company over the next 12 months.
Thermo Fisher Scientific (TMO) forges ahead with initiatives to strengthen its hold in the high-potential human identification market.
Thermo Fisher Scientific Inc., a Waltham, Mass.-based biotechnology product-development company, has acquired IntegenX Inc.
Thermo Fisher Scientific offers products including analytical instruments, reagents, equipment, consumables, diagnostics and research software, and services. The company has registered steady growth over recent years mainly through partnerships, collaborations, and tuck-in acquisitions. Recently, the company has entered a number of research partnerships focused on providing solutions to treat cancer and neurodegenerative diseases. On March 9, 2018, BioDiscovery and Thermo Fisher Scientific announced their partnership for the development of an end-to-end cancer research product.
On February 27, 2018, Thermo Fisher Scientific (TMO) announced the launch of the new Thermo Scientific Chromeleon XTR Laboratory Management system, which was designed to manage an entire laboratory. The software has the ability to support data integrity, process adherence, and regulatory compliance. The system provides enhanced data software capabilities like sample management and data archiving as compared to the traditional CDS (chromatography data systems).